A three-dimensional (3D) biocompatible, degradable soft tissue implant, comprising a bioprinted composite scaffold, the composite scaffold comprising a recombinant human collagen (rhCollagen) and a biocompatible synthetic polymer and features: a porous wall; an inner cavity at least partially enclosed within the porous wall; and at least one injection port that connects the inner cavity with an outer most surface of the scaffold, wherein the injection port has an opening sized to permit insertion of an injection device through the port, processes of preparing same and uses thereof in soft tissue reconstruction are provided. Injectable matrices for use in soft tissue reconstruction, either alone or in combination with the implant are also provided.

The invention relates to a device for use in the transcatheter treatment of mitral valve regurgitation, specifically a coaptation enhancement element for implantation across the valve; a system including the coaptation enhancement element and anchors for implantation; a system including the coaptation enhancement element, catheter and driver; and a method for transcatheter implantation of a coaptation element across a heart valve.

A method is provided for implanting a valve having at least one valve leaflet within the cardiovascular system of a subject. One step of the method includes preparing a substantially dehydrated bioprosthetic valve and then providing an expandable support member having oppositely disposed first and second ends and a main body portion extending between the ends. Next, the substantially dehydrated bioprosthetic valve is attached to the expandable support member so that the substantially dehydrated bioprosthetic valve is operably secured within the main body portion of the expandable support member. The expandable support member is then crimped into a compressed configuration and placed at a desired location within the cardiovascular system of the subject. Either before or after placement at the desired location, fluid or blood re-hydrates the substantially dehydrated bioprosthetic valve.

The invention provides an ex-vivo method, i.e. an in vitro method, for genetically modifying cells of a vascularised tissue, which can be anorgan, during normothermic or subnormothermic perfusion without damaging the tissue or its cells due to oxygen undersupply. The method enables keeping the vascularised tissue at normothermic or subnormothermic conditions over a sufficient period of time to genetically modify the cells e.g. with viral vectors.

An anchor is anchorable to tissue of a ventricle downstream of a heart valve of a subject. Each wing of a pair of wings defines a lateral surface and a medial surface, such that the medial surface of one wing of the pair faces the medial surface of the other wing of the pair. The wings are coupled to the anchor such that, when the anchor is anchored to the tissue, the anchor supports the wings at the valve, with the lateral surface of each wing facing a respective leaflet of the valve. During systole, the lateral surface of each wing is in contact with the respective leaflet, and the medial surfaces of the wings move into contact with each other, obstructing retrograde blood flow. During diastole, the medial surfaces move out of contact with each other, facilitating antegrade blood flow. Other implementations are also described.

The present invention provides a valve material having a long-acting antithrombosis property and a preparation method therefor. The preparation method therefor comprises the following steps: performing glutaraldehyde cross-linking treatment on an animal-derived biological valve material, so that the valve material can resist decomposition for a long time; soaking the treated valve material in a formulation solution containing a cross-linking agent and a modifier for 10-60 min, then increasing the temperature to 30-60° C., and performing heat treatment for 1-12 h; and rinsing the valve material after heat treatment, so as to obtain the valve material. The valve material prepared by the method has excellent antithrombosis and anti-calcification properties, and can effectively solve the problem of calcification and thrombosis in the valve material treated by existing means of glutaraldehyde cross-linking. The valve material prepared by the present method can be used as a valve material required for aortic valve, pulmonary valve, venous valve, mitral valve and tricuspid valve replacement.

The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.

The present invention provides devices for treating functional mitral regurgitation and methods of use thereof. The devices translocate a subject's mitral valve in an apical direction. The devices thereby treat mitral regurgitation while preserving a subject's original mitral valve and chordae tendinae.

A bioprosthetic valve for repairing a deep venous insufficiency in a subject includes a single leaflet from a xenogeneic heart valve attached at natural margins of attachment to a patch of valve wall tissue. The patch may extend axially above and below the leaflet and circumferentially on either side of the leaflet to provide a region for attaching the patch to a fenestration in a host vein. A bioprosthetic valve may be manufactured by excising a portion of a xenogeneic heart valve including a single leaflet and contiguous wall tissue, and may further comprise shaving off excess leaflet tissue from adjacent leaflets. A method of replacing a malfunctioning venous valve in a subject includes providing a bioprosthetic valve as described above and inserting it to the host vein.

This invention relates to the design and function of a compressible valve replacement prosthesis, collared or uncollared, which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.